Our Approach

Ardelyx develops:

  • Drugs that target proteins found in the gut whose activities affect the entire body
  • Drugs that are not absorbed, enabling them to achieve systemic efficacy while avoiding systemic toxicity and side effects

What we do

Targeted Therapeutic Areas

Ardelyx has established a unique approach to drug development with programs targeting gut transporters, receptors, and enzymes

Therapeutic Areas

RDX008

In the area of intestinal sodium blockade, Ardelyx is also developing RDX008, a second generation NHE3 inhibitor.

We plan to have a lead RDX008 molecule by year-end 2011 IND-enabling studies during 2012.